Physician profile
David C Pellegrin
NPI 1679662936
$3,980.50
in general payments reported to CMS, 2019-2025
22 companies · $772 in 2025
The $772 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133 · 2020: $261 · 2021: $360 · 2022: $516 · 2023: $834 · 2024: $1,105 · 2025: $772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,686 · Education: $24.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,686.37 |
| Education | $24.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,693.90 | 2020-2025 | |
| Janssen Biotech, INC. | $915.26 | 2020-2025 | Stelara, Simponi, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $417.22 | 2020-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.36 | 2019-2024 | Trulance |
| Madrigal Pharmaceuticals | $105.38 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $102.44 | 2023-2025 | Voquezna |
| Celgene Corporation | $97.93 | 2021-2023 | Zeposia |
| Allergan, INC. | $76.47 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $67.27 | 2022-2023 | |
| Genzyme Corporation | $57.58 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $46.48 | 2022-2023 | Dificid |
| Ferring Pharmaceuticals INC. | $44.18 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $32.02 | 2024 | Dupixent |
| Redhill Biopharma INC. | $30.21 | 2020-2021 | |
| Mauna Kea Technologies, INC. | $29.98 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $25.61 | 2025 | Wegovy |
| Aimmune Therapeutics, INC. | $20.58 | 2024 | |
| Fresenius Kabi USA, LLC | $19.82 | 2023 | Idacio |
| Braintree Laboratories, INC. | $18.18 | 2023 | Sutab |
| Celltrion USA INC. | $15.71 | 2024 | Vegzelma |
| Capsovision, INC. | $14.44 | 2023 | Capsocam Plus |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Pellegrin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.